Transcribed

Nicole Paulk talks about turning moonshots into companies, why unpopular ideas are the right ones to pursue, and how biotech has to move faster and cheaper to survive.

Gleb Kuznetsov talks about about ditching Google for grad school, what it takes to build a true platform company, and where AI-driven drug discovery is headed.

Andrew Bellinger discusses what it takes to build new drug modalities from scratch, the bold bets and tough calls that shaped Verve’s journey, and lessons in building new companies from first-in-class science.* Editor's note: The interview was recorded following the announcement of Verve's acquisition by Lilly, which has since been completed.

Jake Becraft reflects on making bold bets in mRNA, the journey from lab bench to biotech founder, and the state of science today.(00:00) Introduction to Jake Becraft(00:39) Betting big on mRNA — before it was a proven modality(11:34) Getting your drugs to patients(25:47) The state of modern biomanufacturing(34:30) Medicine is the best investment — and we need policy that reflects that(45:22) Rising to the challenge, as CEO(49:09) Secrets to a healthy cofounder relationship(56:55) Parenting and

Karen Akinsanya unpacks the rise of computational drug discovery, what it takes to prove impact of new technologies, and the importance of setting realistic expectations for AI.(00:00) Introduction to Karen Akinsanya(01:54) Pursuing big technological shifts(06:24) How computation is setting the new standard of speed(10:27) Why you can't develop technology in a vacuum(14:08) Breakthroughs take a lot of patience (and cat videos?)(18:28) The big responsibility with AI(20:41) Breaking down silos and

Sara Kenkare-Mitra talks about resilience, risk, and the kind of leadership it takes to save failing drug programs — and make medicines that matter.(00:00) Introduction to Sara Kenkare-Mitra(00:36) Turning a (nearly) failed program into a bestselling drug(08:33) Learning from industry legends(22:59) Winning for patients, even if others take it across the finish line(27:30) Following your curiosity —and unmet need(37:40) A new era for neurotherapeutics(40:46) Transitioning from large to small

Patrick Hsu reflects on the early days of CRISPR, the power of mentorship, and how AI and open science will reshape the future of research.(00:00) Introduction to Patrick Hsu(01:06) Realizing how big CRISPR would become(06:20) Why Feng Zhang's lab is so high-impact(14:23) How to spot a breakthrough before it happens(18:18) Where the U.S. can't compete with China — and where it can(22:13) How will AI transform the industry — and what's still missing(29:41) Why everyone wins with open science(36:42)